Life Science Investing Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome
Life Science Investing Annexon Biosciences to Host Conference Call and Webcast to Discuss GBS Phase 3 Data
Life Science Investing Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635
Life Science Investing Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones
Radiopharm Theranostics Doses First Patient with 18F-RAD101 in U.S. Phase 2b Imaging Study of Brain MetastasisÂ
SOURCE ROCK ROYALTIES ANNOUNCES FOURTH QUARTER & YEAR-END 2024 RESULTS INCLUDING RECORD ANNUAL FUNDS FROM OPERATIONS
